BlossomHill Therapeutics, Inc. Listed Primary

What the company does

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Its initial development efforts focus on two clinical-stage programs: BH-30643, an investigational OMNI-EGFR inhibitor being evaluated in the SOLARA global Phase 1/2 clinical trial for EGFR-mutant NSCLC, and BH-30236, an investigational CLK inhibitor being evaluated in a Phase 1 trial in R/R AML and HR-MDS. The company is also advancing a preclinical-stage product candidate, BH-501284, which is designed to selectively target and modulate activated KRAS.

Use of proceeds

The company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to advance the clinical development of BH-30643 in EGFR-mutant NSCLC, to advance the clinical development of BH-30236, to complete IND-enabling studies, submit an IND and initiate a Phase 1 clinical trial of BH-501284, and the remainder for other research and development activities, as well as for capital expenditures, working capital and other general corporate purposes.

Underwriters

Extracted from 424B4 0001193125-26-340215, filed Aug 7, 2026 and verified against that filing text.

Key risk factors

• Limited operating history

  “We are a clinical-stage biopharmaceutical company with a limited operating history.”

• Reliance on third parties for preclinical studies and clinical trials

  “We rely on third parties to conduct our preclinical studies and clinical trials.”

• Reliance on third-party manufacturers and suppliers

  “We rely on third-party manufacturers and suppliers to supply our product candidates.”